151 related articles for article (PubMed ID: 38336861)
21. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
Front Immunol; 2018; 9():2140. PubMed ID: 30294328
[TBL] [Abstract][Full Text] [Related]
22. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
23. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
24. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ
Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297
[TBL] [Abstract][Full Text] [Related]
25. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
Kwa MJ; Adams S
Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
[TBL] [Abstract][Full Text] [Related]
26. Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restores the Function of Antiviral Tissue-Resident CD8
Roy S; Coulon PG; Prakash S; Srivastava R; Geertsema R; Dhanushkodi N; Lam C; Nguyen V; Gorospe E; Nguyen AM; Salazar S; Alomari NI; Warsi WR; BenMohamed L
J Virol; 2019 Sep; 93(18):. PubMed ID: 31217250
[TBL] [Abstract][Full Text] [Related]
27. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Gupta T; Vinayak S; Telli M
Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
[TBL] [Abstract][Full Text] [Related]
28. The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1
Li X; Du H; Zhan S; Liu W; Wang Z; Lan J; PuYang L; Wan Y; Qu Q; Wang S; Yang Y; Wang Q; Xie F
Front Immunol; 2022; 13():830606. PubMed ID: 35935985
[TBL] [Abstract][Full Text] [Related]
29. Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer.
Tashireva LA; Kalinchuk AY; Gerashchenko TS; Menyailo M; Khozyainova A; Denisov EV; Perelmuter VM
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674951
[TBL] [Abstract][Full Text] [Related]
30. Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma.
Salisbury T; Abozina A; Zhang C; Mao E; Banyi N; Leo J; Ionescu D; Zhou C; Wang G
Ann Diagn Pathol; 2022 Apr; 57():151901. PubMed ID: 35091156
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
Hou Y; Nitta H; Wei L; Banks PM; Lustberg M; Wesolowski R; Ramaswamy B; Parwani AV; Li Z
Breast J; 2018 Nov; 24(6):911-919. PubMed ID: 30230111
[TBL] [Abstract][Full Text] [Related]
32. Effector memory cytotoxic CD3
Sun X; Zhai J; Sun B; Parra ER; Jiang M; Ma W; Wang J; Kang AM; Kannan K; Pandurengan R; Zhang S; Solis LM; Haymaker CL; Raso MG; Mendoza Perez J; Sahin AA; Wistuba II; Yam C; Litton JK; Yang F
Mod Pathol; 2022 May; 35(5):601-608. PubMed ID: 34839351
[TBL] [Abstract][Full Text] [Related]
33. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
34. PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.
Nagarajan P; El-Hadad C; Gruschkus SK; Ning J; Hudgens CW; Sagiv O; Gross N; Tetzlaff MT; Esmaeli B
Invest Ophthalmol Vis Sci; 2019 May; 60(6):2388-2398. PubMed ID: 31141610
[TBL] [Abstract][Full Text] [Related]
35. LAG-3 expression in tumor microenvironment of triple-negative breast cancer.
Tahtacı G; Günel N; Sadioğlu A; Akyürek N; Boz O; Üner A
Turk J Med Sci; 2023 Feb; 53(1):142-148. PubMed ID: 36945923
[TBL] [Abstract][Full Text] [Related]
36. Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer.
Stovgaard ES; Kümler I; List-Jensen K; Roslind A; Christensen IJ; Høgdall E; Nielsen D; Balslev E
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):62-71. PubMed ID: 34081635
[TBL] [Abstract][Full Text] [Related]
37. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Voorwerk L; Slagter M; Horlings HM; Sikorska K; van de Vijver KK; de Maaker M; Nederlof I; Kluin RJC; Warren S; Ong S; Wiersma TG; Russell NS; Lalezari F; Schouten PC; Bakker NAM; Ketelaars SLC; Peters D; Lange CAH; van Werkhoven E; van Tinteren H; Mandjes IAM; Kemper I; Onderwater S; Chalabi M; Wilgenhof S; Haanen JBAG; Salgado R; de Visser KE; Sonke GS; Wessels LFA; Linn SC; Schumacher TN; Blank CU; Kok M
Nat Med; 2019 Jun; 25(6):920-928. PubMed ID: 31086347
[TBL] [Abstract][Full Text] [Related]
38. Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy.
Wang Z; Cordova LE; Chalasani P; Lu J
Mol Pharm; 2022 Dec; 19(12):4665-4674. PubMed ID: 36413426
[TBL] [Abstract][Full Text] [Related]
39. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.
Ferrando-Martinez S; Snell Bennett A; Lino E; Gehring AJ; Feld J; Janssen HLA; Robbins SH
Front Immunol; 2021; 12():648420. PubMed ID: 34589081
[TBL] [Abstract][Full Text] [Related]
40. Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer.
Yokoi T; Oba T; Kajihara R; Abrams SI; Ito F
Sci Rep; 2021 Nov; 11(1):21992. PubMed ID: 34754037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
